Epizyme, Inc. EPZM
Set alert
1.47 0.00 0.00%
As of Apr 24, 3:47 PM ET
1.47 Day range 1.50
52-week range unavailable
- Open
- 1.49
- Prev close
- 1.47
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.47
- High
- 1.50
- Forward P/E
- -0.67
- Beta
- -0.42
- Short ratio
- 0.78
- Inst. own
- 81.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2022
- 50-d avg
- 1.25
- 200-d avg
- 1.67
- 1y target
- 6.00
Analyst view
Consensus: buy
Buy
Price target (mean) 6.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy5
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 3
- 2 months ago 5
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.41 | -0.41 – -0.41 | -0.64 | +35.9% | 11.50M | 0.0% | 1 |
| Next quarter | -0.59 | -0.59 – -0.59 | -0.49 | -20.4% | 13.02M | +12.4% | 1 |
| Current year | -1.89 | -1.89 – -1.89 | -2.45 | +22.9% | 43.22M | +15.5% | 1 |
| Next year | -2.19 | -2.19 – -2.19 | -1.89 | -15.9% | 91.96M | +112.8% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 28, 2022 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Jun 27, 2022 | Wedbush | Downgrade | Outperform | Neutral |
| Jun 3, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 12, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 2, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 10, 2021 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
| Aug 10, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| May 7, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| May 7, 2021 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Apr 19, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Mar 31, 2021 | Credit Suisse | Initiated | — | Outperform |
| Feb 25, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Dec 21, 2020 | Jefferies | Downgrade | Buy | Hold |
| Nov 9, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Aug 5, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Jun 19, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Jun 19, 2020 | SVB Leerink | Maintained | — | Market Perform |
| May 5, 2020 | Oppenheimer | Maintained | — | Perform |
| Apr 1, 2020 | Oppenheimer | Downgrade | Outperform | Perform |
| Mar 4, 2020 | Barclays | Initiated | — | Overweight |
| Jan 24, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Jan 24, 2020 | Wedbush | Maintained | — | Outperform |
| Jan 23, 2020 | Citigroup | Maintained | — | Buy |
| Dec 6, 2019 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Jan 7, 2019 | Leerink Swann | Upgrade | Market Perform | Outperform |
| Nov 5, 2018 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 25, 2018 | Leerink Swann | Initiated | — | Market Perform |
| Jul 3, 2018 | Leerink Swann | Downgrade | Outperform | Market Perform |
| Apr 24, 2018 | Wedbush | Maintained | Outperform | Outperform |
| Mar 14, 2018 | Leerink Swann | Maintained | Outperform | Outperform |